Meeting
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
Authors
Martin Reck
LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
Martin Reck , Ki Hyeong Lee , Nicolaj Frost , Valeriy Vladimirovich Breder , Dariusz Kowalski , Evgeny Levchenko , Noemi Reguart , Alex Martinez-Marti , Baerin Houghton , Jean-Baptiste Paoli , Sufiia Safina , Takefumi Komiya , Amy Sanford , Hong Liu , Andrew J. Song , Steven M. Keller , Salma K. Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03631784
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8508)
DOI
10.1200/JCO.2022.40.16_suppl.8508
Abstract #
8508
Poster Bd #
135
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
First Author: Salma K. Jabbour
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2021 ASCO Annual Meeting
Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.
First Author: Salma K. Jabbour
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto